Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Genelux Corporation
Eli Lilly and Company
National Institutes of Health Clinical Center (CC)
Qilu Pharmaceutical Co., Ltd.
City of Hope Medical Center
Jiangsu Cancer Institute & Hospital
Ohio State University Comprehensive Cancer Center
GOG Foundation
Icahn School of Medicine at Mount Sinai
Eli Lilly and Company
Merck Sharp & Dohme LLC
Toray Industries, Inc
AstraZeneca
Roswell Park Cancer Institute
The University of Hong Kong
Mayo Clinic
Mercy Medical Center
Eli Lilly and Company
University Hospital, Ghent
CanariaBio Inc.
Emory University
Canadian Cancer Trials Group
Cantonal Hospital of St. Gallen
pharmaand GmbH
Shandong University
Xennials Therapeutics Australia Pty Ltd
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Northwell Health
Holy Name Medical Center, Inc.
Ruhr University of Bochum
Ruhr University of Bochum
Cedars-Sinai Medical Center
AGO Research GmbH
Zhongshan Hospital Xiamen University
Memorial Sloan Kettering Cancer Center
Canadian Cancer Trials Group
University of Maryland, Baltimore
Daiichi Sankyo
Swiss Cancer Institute
University Health Network, Toronto
Critical Outcome Technologies Inc.
GOG Foundation
National Institutes of Health Clinical Center (CC)
Western Regional Medical Center
University of Oklahoma
OHSU Knight Cancer Institute
Columbia University
MEI Pharma, Inc.
Memorial Sloan Kettering Cancer Center